A multi-valent vaccinia virus-based tuberculosis vaccine molecularly adjuvanted with interleukin-15 induces robust immune responses in mice

Vaccine

Volumn 27, Issue 15, 2009, Pages 2121-2127

  Perera, Pin Yu ^a   Derrick, Steven C ^b   Kolibab, Kristopher ^b   Momoi, Fumiki ^c   Yamamoto, Masafumi ^c   Morris, Sheldon L ^b   Waldmann, Thomas A ^d   Perera, Liyanage P ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c NIHON UNIVERSITY   (Japan)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

IL 15; Tuberculosis; Vaccines

Indexed keywords

ANTIGEN 85A; ANTIGEN 85B; BCG VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; HEAT SHOCK PROTEIN 65; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 15; MTB39A ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE TRANSMISSION; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; LUNG TUBERCULOSIS; MODIFIED VIRUS ANKARA; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; VACCINE PRODUCTION; VACCINIA VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CRICETINAE; FEMALE; INTERLEUKIN-15; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TUBERCULOSIS VACCINES; TUBERCULOSIS, MENINGEAL; TUBERCULOSIS, MILIARY; VACCINIA VIRUS;

EID: 61549087491     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.132     Document Type: Article

References (29)

1. http://www.who.int/tb/publications/global_report/en/.
2. Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393 (1998) 537-544
3. Jouanguy E., Altare F., Lamhamedi S., Revy P., Emile J.F., Newport M., et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection. N Engl J Med 335 (1996) 1956-1961
4. Havlir D.V., and Barnes P.F. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 340 (1999) 367-373
5. Rosenzweig S.D., and Holland S.M. Defects in the interferon-gamma and interleukin-12 pathways. Immunol Rev 203 (2005) 38-47
6. Toussirot E., and Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother 5 (2004) 581-594
7. In: Ausubel F.M., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A., and Struhl K. (Eds). Current protocols in molecular biology (2005), John Wiley and Sons, New York
8. Oh S., Berzofsky J.A., Burke D.S., Waldmann T.A., and Perera L.P. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci USA 100 (2003) 3392-3397
9. Gong J.H., Maki G., and Klingemann H.G. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8 (1994) 652-658
10. Derrick S.C., Yang A.L., and Morris S.L. A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis boosts BCG-induced protective immunity. Vaccine 23 (2004) 780-788
11. Gómez C.E., Nájera J.L., Krupa M., and Esteban M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther 8 (2008) 97-120
12. Skeiky Y.A., and Sadoff J.C. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4 (2006) 469-476
13. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6 (2006) 595-601
14. Oh S., Perera L.P., Burke D.S., Waldmann T.A., and Berzofsky J.A. IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells. Proc Natl Acad Sci USA 101 (2004) 15154-15159
15. Perera L.P., Waldmann T.A., Mosca J.D., Baldwin N., Berzofsky J.A., and Oh S.K. Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice. J Virol 8 (2007) 8774-8783
16. Hiroi T., Yanagita M., Ohta N., Sakaue G., and Kiyono H. IL-15 and IL-15 receptor selectively regulate differentiation of common mucosal immune system-independent B-1 cells for IgA responses. J Immunol 165 (2000) 4329-4337
17. Kim P.S., Armstrong T.D., Song H., Wolpoe M.E., Weiss V., Manning E.A., et al. Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. J Clin Invest 118 (2008) 1700-1711
18. Denis O., Tanghe A., Palfliet K., Jurion F., van den Berg T.P., Vanonckelen A., et al. Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. Infect Immun 66 (1998) 1527-1533
19. Goonetilleke N.P., McShane H., Hannan C.M., Anderson R.J., Brookes R.H., and Hill A.V. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 171 (2003) 1602-1609
20. Santosuosso M., McCormick S., Zhang X., Zganiacz A., and Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 74 (2006) 4634-4643
21. Bodmer H.C., Pemberton R.M., Rothbard J.B., and Askonas B.A. Enhanced recognition of a modified peptide antigen by cytotoxic T cells specific for influenza nucleoprotein. Cell 52 (1998) 253-258
22. Beveridge N.E., Price D.A., Casazza J.P., Pathan A.A., Sander C.R., Asher T.E., et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 37 (2007) 3089-3100
23. Pathan A.A., Sander C.R., Fletcher H.A., Poulton I., Alder N.C., Beveridge N.E., et al. Boosting BCG with recombinant modified vaccinia Ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. PLoS ONE 2 (2007) e1052
24. Yoshikai Y., and Nishimura H. The role of interleukin 15 in mounting an immune response against microbial infections. Microbes Infect 2 (2000) 381-389
25. Rausch A., Hessmann M., Hölscher A., Schreiber T., Bulfone-Paus S., Ehlers S., et al. Interleukin-15 mediates protection against experimental tuberculosis: a role for NKG2D-dependent effector mechanisms of CD8+ T cells. Eur J Immunol 36 (2006) 1156-1167
26. Krutzik S.R., Hewison M., Liu P.T., Robles J.A., Stenger S., Adams J.S., et al. IL-15 links TLR2/1-induced macrophage differentiation to the vitamin D-dependent antimicrobial pathway. J Immunol 181 (2008) 7115-7120
27. Behar S.M., Woodworth J.S., and Wu Y. Next generation: tuberculosis vaccines that elicit protective CD8+ T cells. Expert Rev Vaccines 6 (2007) 441-456
28. Mueller Y.M., Makar V., Bojczuk P.M., Witek J., and Katsikis P.D. IL-15 enhances the function and inhibits CD95/Fas-induced apoptosis of human CD4+ and CD8+ effector-memory T cells. Int Immunol 15 (2003) 49-58
29. Picker L.J., Reed-Inderbitzin E.F., Hagen S.I., Edgar J.B., Hansen S.G., Legasse A., et al. IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J Clin Invest 116 (2006) 1514-1524